ICML 2017 | Misconceptions about the use of biosimilars
Laszlo Gulacsi, MD, PhD from Corvinus University Budapest, Budapest, Hungary discusses misconceptions about the use of biosimilars such as rituximab. Prof. Gulasci mentions that not all physicians are well-informed on this topic as some associate risks with the use of biosimilars. However, as he explains, switching studies have shown that switching from an originator biological to a biosimilar does not lead to a worsening of disease.
Recorded at the International Conference on Malignant Lymphoma (ICML) 2017 held in Lugano, Switzerland.
This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.
Get great new content delivered to your inboxSign up